Basic Information
Inbrija
Regulatory Information
EMEA/H/C/004786
September 19, 2019
July 25, 2019
6
January 6, 2025
Company Information
Ireland
10 Earlsfort Terrace Dublin 2, D02 T380
ACORDA THERAPEUTICS IRELAND LIMITED
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.
Overview Summary
Inbrija is a medicine used to treat adults with Parkinson’s disease (a progressive brain disease that causes shaking and muscle stiffness and slows movement). Inbrija is used to treat symptoms during ‘off’ periods (times when the patient has more difficulty moving about) that occur while the patient is taking their usual treatment of a combination of levodopa and an inhibitor of dopa-decarboxylase. Inbrija contains the active substance levodopa.